Improving oncolytic viruses for treating pancreatic cancer
Understanding and improving novel oncolytic viruses for pancreatic cancer
This study is looking at a special virus that can help fight pancreatic cancer by targeting and killing cancer cells while leaving healthy cells alone, and it aims to find out why some cancer cells don't respond to this treatment so that we can make it work better for everyone.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of North Carolina Charlotte NIH-funded |
| Lab location | 1 site (Charlotte, United States) |
| Project ID | NIH-10796294 on NIH RePORTER |
What this research studies
This research focuses on developing and enhancing oncolytic viruses, specifically vesicular stomatitis virus (VSV), to target and destroy pancreatic cancer cells. The approach involves using these viruses to infect cancer cells, leading to their destruction while sparing normal tissues. The study aims to understand why some pancreatic cancer cell lines resist treatment with VSV and to identify ways to overcome this resistance. By analyzing the cellular characteristics of various pancreatic cancer lines, the research seeks to improve treatment outcomes for patients with this aggressive cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with pancreatic ductal adenocarcinoma who may benefit from novel virotherapy treatments.
Not a fit: Patients with non-pancreatic cancers or those who do not have pancreatic ductal adenocarcinoma may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and less toxic treatment options for patients with pancreatic cancer.
How similar studies have performed: Previous studies have shown promise with oncolytic viruses in treating various malignancies, indicating potential for success in this novel approach.
Where this research is happening
Charlotte, United States
- University of North Carolina Charlotte — Charlotte, United States (Active)
Researchers
- Principal investigator: Grdzelishvili, Valery Zurabovich — University of North Carolina Charlotte
- Study coordinator: Grdzelishvili, Valery Zurabovich
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.